CONMED (CNMD)
Makes surgical devices for orthopedic and minimally invasive general procedures.
$46.44
vs last close+1.75 (+3.92%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 305 | 327 | 312 | 332 | 317 | 346 | 319 | 343 | 339 | 373 | 317 | 343 |
| Cost of revenue | 137 | 145 | 140 | 148 | 138 | 148 | 152 | 163 | 181 | 160 | 134 | 146 |
| Gross profit | 168 | 182 | 172 | 184 | 179 | 198 | 168 | 181 | 158 | 213 | 183 | 197 |
| 138 | 132 | 137 | 137 | 113 | 146 | 156 | 139 | 139 | 146 | 158 | 161 | |
| Research & development | 12 | 14 | 14 | 14 | 14 | 13 | 13 | 14 | 14 | 15 | 16 | 16 |
| Selling, general & administrative | 125 | 118 | 123 | 123 | 100 | 133 | 143 | 125 | 125 | 132 | 142 | 146 |
| Operating income | 30 | 50 | 35 | 47 | 66 | 52 | 11 | 42 | 19 | 67 | 25 | 36 |
| −10 | −10 | −10 | −10 | −9 | −9 | −4 | −12 | −15 | −38 | −7 | −5 | |
| Interest expense | 10 | 10 | 10 | 10 | 9 | 9 | 8 | 8 | 8 | 7 | 7 | 8 |
| Other non-operating income | 0 | 0 | 0 | 0 | 0 | 0 | −4 | 4 | 8 | 30 | 0 | −3 |
| Income before tax | 20 | 41 | 25 | 38 | 56 | 44 | 8 | 30 | 4 | 29 | 18 | 31 |
| Income tax expense | 4 | 8 | 6 | 8 | 7 | 10 | 2 | 8 | 1 | 13 | 5 | 8 |
| Net income from continuing operations | 16 | 33 | 20 | 30 | 49 | 34 | 6 | 21 | 3 | 17 | 14 | 23 |
| Net income | 16 | 33 | 20 | 30 | 49 | 34 | 6 | 21 | 3 | 17 | 14 | 23 |
| EPS, basic | $0.52 | $1.08 | $0.64 | $0.97 | $1.59 | $1.09 | $0.19 | $0.69 | $0.09 | $0.54 | $0.45 | $0.77 |
| EPS, diluted | $0.50 | $1.05 | $0.63 | $0.96 | $1.57 | $1.08 | $0.19 | $0.69 | $0.09 | $0.54 | $0.45 | $0.77 |
| Weighted average shares, basic | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 30 |
| Weighted average shares, diluted | 32 | 32 | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 30 |
| EBITDA | 43 | 68 | 53 | 65 | 84 | 71 | 29 | 51 | 25 | 55 | 38 | 61 |
| Depreciation & amortization | 13 | 18 | 18 | 18 | 18 | 18 | 13 | 13 | 13 | 19 | 13 | 22 |
| EBIT | 30 | 50 | 35 | 47 | 66 | 52 | 16 | 38 | 12 | 37 | 25 | 39 |
